TransCode Therapeutics, Inc. RNAZ 深 滬
交易中 04-01 10:45:33 美东时间
8.99
+0.380
+4.41%
華盛通- 最 高9.44
- 今 開8.57
- 成交量 2020股
- 最 低 8.57
- 昨 收 8.61
- 總市值 824.35万
- 52周最高 22.0276
- 市盈率 靜 --
- 換手率 0.22%
- 52周最低 6.0829
- 委 比 0.00%
- 總股本 91.70万
- 歷史最高 5174400.00
- 量 比 2.39
- 振 幅 10.10%
- 歷史最低 6.1488
- 每 手 1
- 風險率 1.94%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多TransCode Therapeutics Delays 2025 Annual Filing
TransCode Therapeutics ( ($RNAZ) ) has released a notification of late filing. ...
今天 10:25
美股夜盘 | Urgent.ly Inc.涨160.10%，STRATS Trust for Allstate Corp Utd Sts Cellular Strats 6.375涨102.02%
Urgent.ly Inc.涨160.10%；STRATS Trust for Allstate Corp Utd Sts Cellular Strats 6.375涨102.02%；Click Holdings Limited Class A涨53.38%
03-16 09:02
TransCode Therapeutics Enters Into Exclusive, Worldwide, Fully Paid-Up Royalty-Free License Agreement With Unleash Immuno Oncolytics
TransCode adds a unique adenovirus technology platform to its early-stage pipeline that has the potential to address a difficult to treat disease such as muscle-invasive bladder cancer.BOSTON, March 3, 2026 /PRNewswire/
03-03 21:19
TransCode Therapeutics Secures Royalty-Free Worldwide License for Oncolytic Immunotherapy Candidates
TransCode Therapeutics Secures Royalty-Free Worldwide License for Oncolytic Immunotherapy Candidates TransCode Therapeutics Inc. said it entered an exclusive, worldwide, fully paid-up royalty-free license agreement with Unleash Immuno Oncolytics, Inc. to develop three drug candidates, UIO-524, UIO-5
03-03 21:03
TransCode Therapeutics licenses Unleash oncolytic immunotherapy platform in all-stock deal
TransCode Therapeutics licenses Unleash oncolytic immunotherapy platform in all-stock deal TransCode Therapeutics entered an exclusive, worldwide, fully paid-up royalty-free license agreement with Unleash Immuno Oncolytics for rights to develop and commercialize three oncolytic immunotherapy candida
03-03 21:01
TransCode Therapeutics Publishes Preclinical Results for Tumor-Selective RIG-I Immunotherapy Candidate
TransCode Therapeutics Publishes Preclinical Results for Tumor-Selective RIG-I Immunotherapy Candidate TransCode Therapeutics Inc. announced the publication of preclinical testing results for a tumor-selective RIG-I immunotherapeutic candidate in *Molecular Imaging and Biology*. The published study
02-23 21:03
Transcode Therapeutics In Collaboration With Quantum Leap Healthcare Collaborative, Submitted An FDA Investigational New Drug Application Amendment For Planned Phase 2A Trial With Transcode's TTX-MC138
As part of the PRE-I-SPY platform, the TTX-MC138 Phase 2a dose-expansion portion of the trial will enroll up to 45 patients with colorectal cancer who have completed standard curative-intent therapy and have
02-05 21:15
TransCode Announces Collaboration for Phase 2a Trial
TransCode Therapeutics ( ($RNAZ) ) has shared an announcement. On December 11, ...
2025-12-11 21:28
BRIEF-TransCode Therapeutics And Quantum Leap Healthcare Collaborative Launch A Phase 2A Dose-Expansion Trial With TTX-MC138, Following Positive Readouts From TransCode's Phase 1 Trial
Dec 11 (Reuters) - Transcode Therapeutics Inc RNAZ.O: TRANSCODE THERAPEUTICS AND QUANTUM LEAP HEALTHCARE COLLABORATIVE LAUNCH A PHASE 2A DOSE-EXPANSION TRIAL WITH TTX-MC138, FOLLOWING POSITIVE READOUT...
2025-12-11 21:08
TransCode Therapeutics and Quantum Leap Launch Phase 2a Trial for TTX-MC138 in Colorectal Cancer
TransCode Therapeutics Inc. has announced a new collaboration with Quantum Leap Healthcare Collaborative to evaluate its lead therapeutic candidate, TTX-MC138, as part of the Quantum Leap PRE-I-SPY cl...
2025-12-11 21:05
